A double blind, randomised, three-period, crossover, placebo controlled study to evaluate the effects of supratherapeutic dose of Doravirine on the heart rate QTc interval in healthy adults

Trial Profile

A double blind, randomised, three-period, crossover, placebo controlled study to evaluate the effects of supratherapeutic dose of Doravirine on the heart rate QTc interval in healthy adults

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Doravirine (Primary) ; Moxifloxacin
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Aug 2017 New trial record
    • 07 Aug 2017 Results published in the Clinical Drug Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top